CytoAgents has filed a notice of an exempt offering of securities to raise $15,204,008.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CytoAgents is raising $15,204,008.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Teresa Whalen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About CytoAgents
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts lead drug candidate, GP1681, is positioned to become a new best practice in medicine.
To learn more about CytoAgents, visit http://www.cytoagents.com/
Contact:
Teresa Whalen, Chief Executive Officer
412-303-1200
https://www.linkedin.com/in/teresawhalen/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.